Evidence map›Paper›PMID 39145537›Full record

ArticleACS chemical neuroscience2024

The Usnic Acid Analogue 4-FPBUA Enhances the Blood-Brain Barrier Function and Induces Autophagy in Alzheimer's Disease Mouse Models.

Sweilem B Al Rihani, Khaled H Elfakhri, Hassan Y Ebrahim, Nour F Al-Ghraiybah, Amer E Alkhalifa, Khalid A El Sayed, Amal Kaddoumi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS chemical neuroscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sweilem B Al RihaniDepartment of Drug Discovery and Development, Harrison College of Pharmacy, Pharmacy Research Building, Auburn University, Auburn, Alabama 36849, United States.
Khaled H ElfakhriSchool of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, Monroe, Louisiana 71201, United States.
Hassan Y EbrahimSchool of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, Monroe, Louisiana 71201, United States.
Nour F Al-GhraiybahDepartment of Drug Discovery and Development, Harrison College of Pharmacy, Pharmacy Research Building, Auburn University, Auburn, Alabama 36849, United States.
Amer E AlkhalifaDepartment of Drug Discovery and Development, Harrison College of Pharmacy, Pharmacy Research Building, Auburn University, Auburn, Alabama 36849, United States.
Khalid A El SayedSchool of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, Monroe, Louisiana 71201, United States.ORCID 0000-0002-1456-4064
Amal KaddoumiDepartment of Drug Discovery and Development, Harrison College of Pharmacy, Pharmacy Research Building, Auburn University, Auburn, Alabama 36849, United States.ORCID 0000-0001-9792-7766

Funding

Targeting cerebrovascular endothelial cells as a therapeutic approach for amyloid pathogenesisR15NS091934 · NINDS · UNIVERSITY OF LOUISIANA AT MONROE · PI KHALIL KADDOUMI, AMAL F · 2015 to 2015
$420k
NINDS NIH HHS R15 NS091934
6 · The paper itself

Abstract

Preclinical and clinical studies have indicated that compromised blood-brain barrier (BBB) function contributes to Alzheimer's disease (AD) pathology. BBB breakdown ranged from mild disruption of tight junctions (TJs) with increased BBB permeability to chronic integrity loss, affecting transport across the BBB, reducing brain perfusion, and triggering inflammatory responses. We recently developed a high-throughput screening (HTS) assay to identify hit compounds that enhance the function of a cell-based BBB model. The HTS screen identified (

Indexed as

Alzheimer DiseaseAutophagyBenzofuransBlood-Brain BarrierDisease Models, AnimalAmyloid beta-PeptidesAnimalsHumansMiceMice, TransgenicAmyloid beta-PeptidesBenzofuransusnic acid4-FPBUAAlzheimer’s diseaseAMPK pathwayautophagyblood−brain barriermTOR pathwayusnic acidusnic acid analogue

Identifiers

PMID39145537
PMCPMC12936885

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.